Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JMKX000197 in Malignant Pleural Effusion
NCT05923515Phase 1Unknown
- Sponsor
- Jemincare
- Start
- May 2023
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of JMKX000197 in malignant pleural effusion (MPE) (8 arms), sponsored by Jemincare. Primary endpoints: Incidence of Dose Limiting Toxicity at 7 days, Maximum Tolerated Dose at 24 months and 1 more. Status: unknown.
02
Drugs
JMKX000197
03
Conditions
malignant pleural effusion (MPE)
Beyond the preview
Go deeper on NCT05923515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05923515.